Evid Invest
Who owns GSKWhat GSK owns

What GSK plc owns

The company's own 13F portfolio · as of 2026-03-31 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F

$599.2M

disclosed stock portfolio

13

positions

25.6%

in CRISPR

Positions, as of 2026-03-31

ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1CRISPR THERAPEUTICS AG3.2M$153.2M25.6%
2WAVE LIFE SCIENCES LTD18.2M$132.3M22.1%
3BNTXBIONTECH SE889,824$79.1M13.2%
4VIRVIR BIOTECHNOLOGY INC8.6M$76.6M12.8%
5IDYAIDEAYA BIOSCIENCES INC1.3M$44.4M7.4%
6LYELL IMMUNOPHARMA INC1.5M$30.3M5.1%
7CYTKCYTOKINETICS INC340,434$22.4M3.7%
8SPERO THERAPEUTICS INC9.2M$21.5M3.6%
9FULCFULCRUM THERAPEUTICS INC1.8M$13.7M2.3%
10CVRX INC1.0M$9.5M1.6%
11BICYCLE THERAPEUTICS PLC1.5M$7.1M1.2%
12NKARTA INC3.2M$6.6M1.1%
13REGENXBIO INC271,456$2.3M0.4%

Source: SEC Form 13F-HR filed by GSK plc (CIK 1131399), reporting period 2026-03-31. Values are quarter-end filed marks. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.